Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Lannett Reports Strong Fiscal 2009 First-Quarter Financial Results
Nov 13, 2008 04:10 PM
- Lannett Company to Report Fiscal 2009 First-Quarter Financial Results and Host Conference Call on Thursday, November 13, 2008
Nov 11, 2008 07:55 AM
- Lannett Receives Patent Approval for Method of Manufacturing Certain Morphine Derivatives
Oct 08, 2008 07:56 AM
- Lannett Announces Positive Results of Facilities Inspection
Oct 06, 2008 07:58 AM
- Lannett Reports Fiscal 2008 Fourth Quarter, Full-Year Financial Results
Sep 29, 2008 04:26 PM
- Lannett Company Announces William Farber, Chairman of the Board, Takes Medical Leave
Sep 10, 2008 04:35 PM
- Lannett Announces Immediate Availability of Bulk Packs
Aug 15, 2008 07:55 AM
- Lannett Company Receives FDA Approvals for Doxycycline Tablets, 75 mg and 150 mg
Aug 01, 2008 08:04 AM
- Lannett Company Granted Import License from DEA
Jul 28, 2008 07:55 AM
- Lannett Company Comments on Litigation with KV Pharmaceuticals
Jul 25, 2008 07:56 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
LCI
|
Compare to S&P
|
| YTD |
-23.95 %
|
45.72 %
|
| 4 Weeks |
-25.40 %
|
-17.05 %
|
| 12 Weeks |
-29.22 %
|
12.48 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 600.00 %
|
|
EPS Growth in Last Year: 600.00 %
|
|
Sales Growth in Last Quarter: 23.23 %
|
|
Sales Growth in Last Quarter: 46.10 %
|
|
|
